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Background: To induce peroxisomal proliferator-activated receptor α (PPARα) expression and increase milk fat utilization
in pigs at birth, the effect of maternal feeding of the PPARα agonist, clofibrate (2-(4-chlorophenoxy)-2-methyl-propanoic
acid, ethyl ester), on fatty acid oxidation was examined at full-term delivery (0 h) and 24 h after delivery in this study.
Each group of pigs (n = 10) was delivered from pregnant sows fed a commercial diet with or without 0.8% clofibrate for
the last 7 d of gestation. Blood samples were collected from the utero-ovarian artery of the sows and the umbilical cords
of the pigs as they were removed from the sows by C-section on day 113 of gestation.
Results: HPLC analysis identified that clofibric acid was present in the plasma of the clofibrate-fed sow (~4.2 μg/mL)
and its offspring (~1.5 μg/mL). Furthermore, the maternal-fed clofibrate had no impact on the liver weight of
the pigs at 0 h and 24 h, but hepatic fatty acid oxidation examined in fresh homogenates showed that clofibrate
increased (P < 0.01) 14C-accumulation in CO2 and acid soluble products 2.9-fold from [1-
14C]-oleic acid and 1.6-fold from
[1-14C]-lignoceric acid respectively. Correspondingly, clofibrate increased fetal hepatic carnitine palmitoyltransferase (CPT)
and acyl-CoA oxidase (ACO) activities by 36% and 42% over controls (P < 0.036). The mRNA abundance of CPT I
was 20-fold higher in pigs exposed to clofibrate (P < 0.0001) but no differences were detected for ACO and
PPARα mRNA between the two groups.
Conclusion: These data demonstrate that dietary clofibrate is absorbed by the sow, crosses the placental
membrane, and enters fetal circulation to induce hepatic fatty acid oxidation by increasing the CPT and ACO
activities of the newborn.
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High postnatal mortality has been recognized as a crit-
ical problem by the modern swine industry since the
1990’s. Although genetic improvement has increased the
number of pigs born alive per litter, the death rate of
newborn pigs during the postnatal period has increased
slightly in recent years, from 13.2% in 2006 [1] to 14.8%
in 2010 [2]. The epidemiology of postnatal mortality is
complex, but data clearly show that inadequate energy
(starvation) ranks among the leading causes, especially* Correspondence: lin_xi@ncsu.edu
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unless otherwise stated.in the first three days after birth. The immediate postnatal
period poses the greatest challenge to the energy balance
of neonates, which must rapidly switch from carbohy-
drates supplied by the mother in utero [3] to predomin-
antly lipids supplied via milk. Sow milk fat concentration
is about 6% at birth and increases to 10% within 24 h. This
is 67–70% higher than human colostrum (3.5–6%) and
constitutes up to 60% of the energy in the milk, indicating
that the milk fat is the primary energy source for newborn
pigs after birth. Thus, it is critical for newborn pigs to use
milk fat efficiently at birth to survive. However, results
from previous studies show that over 85% of the fatty
acids taken up by newborn pig hepatocytes are re-esterifieds is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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produced from fatty acid β-oxidation in mitochondria
and/or peroxisomes is converted to acetate rather than
ketone bodies [5]. These results indicate that newborn
pigs have a limited capacity to oxidize milk fat for en-
ergy production at birth.
Hepatic fatty acid β-oxidation pathways are controlled
mainly by the key enzymes carnitine palmitoyltransferase
I (CPT I) in mitochondria and acyl-CoA oxidase (ACO)
in peroxisomes. The activities of these key enzymes are
transcriptionally regulated by the peroxisomal proliferator-
activated receptor α (PPARα; [6]). This central transcrip-
tion factor, PPARα, can be activated by its natural ligands
such as eicosanoids and long-chain fatty acids or a
host of pharmaceutical agonists including fibrates, a
class of amphipathic carboxylic acids. Clofibrate, a potent
pharmaceutical PPARα agonist of the fibrate class, stim-
ulates hepatic mitochondrial and peroxisomal fatty acid
β-oxidation by inducing PPARα target genes such as CPT
I and ACO mRNA expressions and protein activities. The
induction of CPT I and ACO by clofibrate via activation
of PPARα has been documented in rodent species [7],
laying hens [8], dairy cows [9] and pigs [10,11]. Data
from our previous studies showed that the total CPT
and ACO activity increase 2- and 3-fold respectively in
the livers of pigs fed clofibrate for 2 weeks. Feeding
clofibrate also increases hepatic peroxisomal and mito-
chondrial β-oxidation of [1-14C]-palmitate by 60% and
186%, respectively, in addition to the increased CPT I
and ACO specific activities [10]. Moreover, the increase in
hepatic fatty acid oxidation is not accompanied by a sig-
nificant hyperplasia or hepatomegaly [12] as observed in
rodent species. These results indicate that the fatty acid
oxidative capacity of pigs could be promoted via induction
of PPARα without substantial peroxisome proliferation.
Recently we have demonstrated that supplementation
of clofibrate could improve in vivo fatty acid oxidation
in neonatal pigs [13]. However, increasing the fatty acid
oxidative capacity of pigs at birth appears to be the key
to improving energy utilization and increasing surviv-
ability. The question is whether the activities of CPT I
and ACO can be increased by activation of PPARα pre-
natally. Whether PPARα agonist can be delivered to the
newborn pigs via maternal diet is not known. Research
concerning the impact of maternal feeding of clofibrate
during pregnancy on fetal fatty acid oxidative capacity at
birth or/and development after birth is very limited.
Maternal dietary clofibrate induced peroxisomal prolif-
eration in the liver and intestine tissues, and induced
enterocyte peroxisomal catalase and peroxisomal bifunc-
tional enzyme activities of fetuses in rats [14]. Maternal
clofibrate also amplified fetal liver endoplasmic reticulum
and peroxisomes, and increased the concentrations of per-
oxisomal membrane protein 70, the specific activity ofdihydroxyacetone phosphate acyltransferase and catalase
in the livers of fetal mice [15]. The relative expression of
cytochrome P4504A mRNA was increased in the maternal
liver and fetal rat tissues [16]. Furthermore, the increase in
relative mRNA of ACO, CPT I, medium- and long-chain
acyl-CoA dehydrogenases in the liver were also observed
in fetal rats from the clofibrate-treated maternal rats [17].
These findings demonstrate that clofibrate is capable of
crossing the placenta and increasing peroxisome prolifera-
tion and modulating specific gene expression. Therefore,
we hypothesize that similar placenta transfer may occur in
pigs, although the physiology of extra embryonic mem-
brane attachment in swine are different from rodents and
other species. The placental transfer of clofibrate has not
been studied directly by measuring clofibrate in the circu-
lation system of the pregnant animals and their fetuses,
and the effect of the induction in enzyme activities and
mRNA expression on fatty acid oxidative capacity is not
known.
To test our hypothesis, we investigated the effect of
maternal supplementation of PPARα agonist clofibrate
on the development of oxidative capacity of newborn
pigs at birth and 24 h after birth. We confirmed that
PPARα agonist clofibrate transfers across porcine pla-
cental tissues by measuring maternal and fetal plasma
clofibrate concentrations and increases hepatic oxidative
capacity by measuring hepatic fatty acid oxidation in the
newborns using [1-14C]-fatty acid substrates.
Methods
Animals, treatments and sampling
All procedures were approved by the Institutional Animal
Care and Use Committee of North Carolina State Univer-
sity (IACUC number: 07-001-A). Twenty newborn pigs
from either control (n = 10, body weight = 1.37 ± 0.047 kg)
or clofibrate fed (n = 10, body weight = 1.20 ± 0.024 kg)
sows were used in this study. Pregnant multiparous cross-
bred sows were housed at the North Carolina State
University Swine Education Unit and were fed a standard
gestation diet (3,265 Kcal ME/kg) with or without supple-
mentation of 0.8% colfibrate (w/w) from day 105 of gesta-
tion until day 113. The clofibrate was diluted into 10 mL
of ethanol and pre-mixed with ~50 g of feed each day.
Sows were fed the premixes (clofibrate or vehicle) together
with ~1/3 of their daily feed allotment first, to ensure
complete consumption, and then the remaining 2/3
allotment was provided. The sows were given 1.75 kg
diets per day in total and water was supplied ad libi-
tum. Term fetuses were delivered by caesarian section
on d 113 of gestation and plasma was collected simul-
taneously from the utero-ovarian artery of swine and
from the umbilical vein of each fetal pig.
All newborn pigs were weighed and euthanized by
AVMA-approved electrocution at time 0 (term fetus,
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at 24 h were housed at 35°C in a specialized nursery
facility [18] and remained un-fed. Liver samples were
immediately homogenized in a buffer (220 mmol/L
mannitol, 70 mmol/L sucrose, 2 mmol/L HEPES, and
0.1 mmol/L EDTA; pH 7.2 at 0°C) using a 7 mL glass
Pyrex hand homogenizer with 3 complete top to bottom
strokes. Fatty acid oxidation in the fresh homogenate
was measured immediately using [1-14C]-fatty acids.
Homogenate protein was determined using the biuret
method [19]. Samples were also immediately frozen in




ethyl ester), clofibric acid (2-(4-chlorophenoxy)-2-
methylpropionic acid), 4-chlorophenylacetic acid and
its metabolites in the plasma from the sows and term
fetuses were extracted using solid-phase extraction
(SPE) procedures as described by Du et al. [20]. The
extraction was conducted using SPEC.C18 extraction
cartridges (Ansys Technologies, CA, and USA). The
clofibrate, clofibric acid, and other lipophilic compo-
nents were eluted with a solvent mixture of aceto-
nitrile : water : formic acid (79% : 20% : 1%, v/v/v)
and were analyzed using a Waters HPLC Empower system
(Milford, MA. USA). The separation of clofibrate, clofibric
acid, and their metabolites was performed on a BDS
Hypersil C18 (5 μm, 150 mm × 46 mm) analytical column
with BDS C18 (5 μm, 4 mm × 3.0 mm) guard column
from Phenomenex (Torrance, CA. USA). The isocratic
HPLC system was used and the pump flow rate was set at
1 mL/min. The sample injection volume was 20 μL and
the compounds were detected at 230 nm using a photo-
diode array detector (Waters 996).
Fatty acid oxidation
Hepatic fatty acid oxidations were measured in fresh liver
homogenates from the pigs at 0 or 24 h without suckling
after delivery using [1-14C]-oleic acid (C18:1, the most
enriched fatty acid in pig milk) and [1-14C]-lignoceric acid
(C24:0, primary oxidized in peroxisomes) as substrates.
The measurements followed the same procedure as de-
scribed previously by Lin et al. [5]. Specifically, liver
homogenates (~40 mg) were incubated in 25 mL Erlen-
meyer flasks with a final of volume of 2 mL of the reac-
tion medium with or without addition of antimycin A
(50 μmol/L) and rotenone (10 μmol/L) described as
previously [13] for determining peroxisomal β-oxidation
by inhibition of the electron transport chain of oxidative
phosphorylation. The reaction was initiated by adding
2 μmol of either [1-14C]-C18:1 (4.2 MBq/mmol) or [1-14C]-
C24:0 (1 MBq/mmol) and terminated by adding 0.5 mLHCLO4. The
14CO2 collected in ethanolamine and
the 14C-acid soluble products (ASP) processed from
the acid-killed medium were quantified using liquid
scintillation counter (Beckman LS 6000IC. Fullerton,
CA. USA). The rate of total β-oxidation and the rate
of peroxisomal and mitochondrial β-oxidation were
calculated as described by Yu et al. [11].
Enzyme and mRNA analysis
Hepatic ACO activity was determined in liver homoge-
nates using a spectrophotofluorometric assay as described
by Walusimbi-kisitu and Harrison [21] with slight modifi-
cations. The homogenates were prepared in an ice cold
buffer containing 250 mmol/L sucrose, 1 mmol/L EDTA
and 1% ethanol. After preparation, the homogenate (0.6 ±
0.035 mg protein) was incubated in a dark room at 37°C
in 0.5 mL (final vol.) of a medium with or without
35 μmol/L palmitoyl-CoA for 20 min. The incubations
were stopped by adding 2 mL of borate buffer (0.1 mol/L,
pH 10). The medium contained 60 mmol/L Tris–HCl,
50 μmol/L FAD, 170 μmol/L CoA, 1 μmol/L scopoletin
and 6% of BSA. 200 μL of the incubated medium was
transferred into a 96 well plate and measured in a BioTek
reader (Synergy HT) with emission at 460 and excitation
at 360 nm (BioTek Instruments, Inc., Winooski, VT). The
standard curve was generated using H2O2 (30%, w/w) and
150 IU peroxidase under the same incubation conditions
and measurements.
CPT activity was measured in liver homogenates using
a radio-enzymatic method as described previously by
Bremer et al. [22]. The homogenate (65 ± 3.8 mg protein)
was pre-incubated with 80 μmol/L palmitoyl-CoA in a
medium containing 75 mmol/L KCl, 50 mmol/L HEPES,
0.2 mmol/L EGTA, and 1% of fatty-acid-free BSA in the
presence or absence of 2.5 μmol/L malonyl-CoA, and the
incubation was conducted at 30°C in a final volume of
1 mL for 3 min [5]. The measurement of the enzyme
activity was initiated with 1 μmol of (l-methyl-3H)-carnitine
(54 KBq/μmol) and terminated after 6 min by the addition
of 2 mL of 6% of HClO4 (vol/vol). The radioactivity in
palmitoyl-carnitine, generated during the incubation was
extracted with water-saturated butanol and quantified using
liquid scintillation spectrometry (Beckman LS 6000IC,
Fullerton, CA. USA).
Assay of mRNA was conducted using the methods
described by Lin et al. [5]. Total RNA was extracted
from the liver samples using guanidine isothiocynate
and phenol (TRIzol Reagent, Sigma Chemical, St. Louis,
MO. USA). The extracted RNA was quantified using a
NanoDrop spectrophotometer (NanoDrop Technologies,
Wilmington, DE. USA), and the integrity of the RNA was
confirmed using gel electrophoresis with SYBR Safe
TM DNA gel stain from Invitrogen Life Technologies
(Carlsbad, CA. USA). The RNA (10 μg/50 μL) then
Lin et al. Journal of Animal Science and Biotechnology  (2015) 6:11 Page 4 of 12was treated with TuboDNase (Ambion, Austin, TX) ac-
cording to the manufacturer’s instructions for removal
of genomic DNA and transcribed using the iScriptTM
Select cDNA Synthesis Kit provided with oligo (dT)
primer mix. (Bio-Rad Laboratories, Hercules, CA). The
mRNA abundance of PPARα, CPT I (L isoform) and
ACO were determined using the MyiQ Single Color
Real-Time PCR Detection System (Bio-Rad Laboratories,
CA. USA). The determination was performed in triplicate
with primers designed from pig-specific sequences
available via GenBank and ordered from Sigma Genosys
(St Louis, MO, USA). Amplification efficiencies were
verified to be similar for the endogenous control GAPDH
and the measured genes. Reactions contained cDNA with
0.4 μmol/L each of reverse and forward primers. The
assay conditions and data calculations were the same
as described previously [5].Chemicals
Clofibrate was purchased from Cayman Chemical Company
(Ann Arbor, MI. USA). [1-14C]-oleic acid (C18:1) and
[1-14C]-lignoceric acid (C24:0) were purchased from
American Radiolabeled Chemicals, Inc. (St. Louis,
MO. USA). 2-(4-Chlorophenoxy)-2-methylpropionic
acid ethyl ester, 2-(4-chlorophenoxy)-2-methylpropionic
acid, 4-chlorophenylacetic acid, peroxidase and all other
chemicals were obtained from Sigma-Aldrich (St. Louis,
MO. USA).A. Control sow
C. Treated sow
Figure 1 Chromatogram of plasma samples from HPLC analysis. A. co
and D. term pigs from clofibrate-treated sow. See Methods for HPLC cond
injection of available standards purchased from Sigma-Aldrich (St. Louis,Statistics
Data from fatty acid oxidation measurements were ana-
lyzed according to a split-plot design with the main plots
in a completely randomized design using the SAS
GLM procedure. The clofibrate effect was assigned to
the main plot and pig postnatal age and fatty acid
chain length effects were treated as the subplots.
Least squares means ± SEM for variables are pre-
sented in tables and figures. Data from enzyme activ-
ity and mRNA enrichment assays were analyzed as a
2 × 2 factorial design using the GLM procedure. Least
square means for treatment (clofibrate vs. control)
and the postnatal age (0 vs. 24 h) effects were calcu-
lated. Differences between least squares means were
determined using a Tukey test and considered signifi-
cant when P ≤ 0.05.Results
Plasma assay
Chromatograms from HPLC analysis confirmed that clo-
fibric acid was present in the plasma of both the
clofibrate-fed sow and their newborn pigs (Figure 1).
In addition to clofibric acid, a clofibrate conjugate metab-
olite was detected in the plasma of the clofibrate-fed sow
but not in the plasma of newborn pigs. An unidentified
peak after the reagent peak was observed also in the chro-
matogram from the plasma analysis of the clofibrate-fed
sow and the peak was tiny in the plasma of newborn pigsB. Term fetus from
control sow
D. Term fetus from
treated sow
ntrol sow, B. newborn pigs from control sow, C. clofibrate-treated sow
itions and sample injection volumes. Compounds were identified by
MO) under the same HPLC conditions. *Unidentified peak.
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its metabolites were detected in the plasma of control
sows or their offspring.
Fatty acid oxidation
Results from total fatty acid oxidation in vitro (Figure 2)
showed that clofibrate and postnatal age significantly
stimulated hepatic β-oxidation of fatty acids (P < 0.0001),
but the stimulatory effects of clofibrate and postnatal
age for C18:1 oxidation were different from C24:0 oxidation.
The 14C accumulations for C18:1 on average in CO2, ASP
and CO2 +ASP (μmol/h/g protein) measured at 0 h and
24 h were 1.9, 2.2, and 2.1 fold higher, respectively,
from clofibrate exposed pigs (2.32, 13.36 and 15.69) than
control pigs (1.24, 6.17 and 7.41). Similarly, the 14C accu-
mulations in CO2, ASP and CO2 +ASP (μmol/h/g protein)Figure 2 The effect of maternal clofibrate on total (mitochondrial and
24 h after delivery by C-section. Total 14C labeled carbon accumulated in
least square means ± SEM (n = 6 for newborn pigs at 0 h and n = 4 for pigs
differ (P < 0.05).for C18:1 from both clofibrate treatment and control were
on average 331%, 49% and 71% greater respectively in the
livers of 24 h old pigs (2.89, 11.69 and 14.58) than the pigs
at delivery (0.67, 7.83 and 8.51). In contrast with
C18:1, the 14C accumulation for C24:0 on average in
CO2 + ASP (μmol/h/g protein) measured at 0 h and
24 h was 1.8 fold higher from clofibrate exposed pigs
(3.32) than control pigs (1.81), but no differences were
detected in the 14C accumulation in CO2 and ASP
(Figure 2, A & B). In addition, the 14C accumulation in
CO2 from C24:0 was increased on average by 61% in
the livers of 24 h old fasted pigs compared to the pigs
at delivery (0.32), but there was no postnatal age effect
on the 14C accumulations in ASP and CO2 +ASP (Figure 2,
B & C). There was no interaction between clofibrate and
pig postnatal age (P > 0.05).peroxisomal) fatty acid oxidation in newborn pigs at 0 h and
CO2 (A), acid soluble products (ASP, B) and CO2 + ASP (C). Values are
at 24 h). abcde Bars within a panel lacking a common superscript
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ASP (Figure 3, A & B) as well as the total (CO2 + ASP,
Figure 3, C) was affected by the treatment of clofibrate
and the postnatal age (P < 0.0001). The 14C-accumula-
tions in CO2, ASP and CO2 + ASP (μmol/h/g protein) in
the livers of the pigs from sow received clofibrate (2.3,
13.1 and 15.5 respectively) were on average 2.1-fold
higher than that from controls (1.2, 6.2 and 7.4 respect-
ively). Similarly, the 14C-accumulations in CO2, ASP and
CO2 + ASP also were increased on average by 3.1, 0.49
and 0.71 fold respectively in the pigs at 24 h after deliv-
ery (2.9, 11.7 and 14.6) as compared to the pigs at birth
(0.7, 7.8 and 8.5). However, the stimulatory effect by clo-
fibrate on the 14C-accumulations in ASP and CO2 + ASP
tended to attenuate with the increase in postnatal age.
There was no effect of age on the 14C accumulation in ASP
in the pigs exposed to clofibrate (Figure 3B; P = 0.079). In
contrast to C18:1, the mitochondrial oxidative flux of C24:0Figure 3 The effect of maternal clofibrate on mitochondrial fatty acid ox
Total 14C labeled carbon accumulated in CO2 (A), acid soluble products (ASP, B
newborn pigs at 0 h and n = 4 for pigs at 24 h). abcd Bars within a panel lackingto ASP and CO2 +ASP (μmol/h/g protein) remained simi-
lar in the livers of the pigs exposed to clofibrate (0.3, 0.83)
and the controls (0.4, 0.9), although the flux to CO2 tended
to be higher in the liver from the clofibrate-exposed pigs
than control pigs. There was no significant change in
the oxidative flux of C24:0 as the postnatal age increased
(P > 0.05).
No substantial 14C-accumulation in CO2 (<0.25, μmol/h/g
protein) was detected in peroxisomes (Figure 4, A).
Clofibrate exposure and postnatal age had no impact
on the negligible peroxisomal oxidative flux to CO2
from C18:1, but significantly increased the flux to ASP
and CO2 + ASP (P < 0.0001; Figure 4, B & C). The
14C
accumulation in the ASP and CO2 + ASP (μmol/h/g
protein) from C18:1was on average 2 fold greater from
clofibrate-treated (5.4, 5.5) than control (2.7, 2.7) pigs,
and 56% higher from the 24 h-old pigs than that from
pigs at delivery (1.3, 1.7). In comparison to C18:1,idation in newborn pigs at 0 h and 24 h after delivery by C-section.
) and CO2 + ASP (C). Values are least square means ± SEM (n = 6 for
a common superscript differ (P< 0.05).
Figure 4 The effect of maternal clofibrate on peroxisomal fatty acid oxidation in newborn pigs at 0 h and 24 h after delivery by C-section.
Total 14C labeled carbon accumulated in CO2 (A), acid soluble products (ASP, B) and CO2 + ASP (C). Values are least square means ± SEM (n = 6
for newborn pigs at 0 h and n = 4 for pigs at 24 h). abcd Bars within a panel lacking a common superscript differ (P < 0.05).
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oxisomal oxidation in CO2 in the liver of pigs at delivery
but decreased in the liver of 24 h-old pigs. Thus there was
no significant difference (P = 0.93) in the average flux to
CO2 (μmol/h/g protein) between clofibrate-treated (0.15)
and control pigs (0.14). There were no effects of clofibrate
on the 14C accumulation in ASP and CO2 + ASP from
C24:0 in pigs at delivery, but the 14C accumulations was
84% greater from clofibrate-treated (4.0) than control in
24 h-old pigs (2.17). Postpartum age also had no influ-
ence on C24:0 oxidation in pigs at delivery (P > 0.05),
but the 14C accumulation in ASP and CO2 + ASP was
94% higher from the clofibrate-treated pigs measured
at 24 h (4.0) than at delivery (2.06).
Clofibrate and postnatal age had no effect on the distri-
bution of oxidative flux C18:1 and C24:0 between mito-
chondria and peroxisome (Figure 5, P > 0.05). However,
the peroxisomal proportion of total fatty acid oxidationwas on average 2.3 fold higher from C24:0 (85.5) than
C18:1 (37.7%).
Enzyme activity and mRNA expression
Hepatic CPT specific activity (Figure 6A) measured with
and without malonyl-CoA was 69% and 43% higher, re-
spectively, in the clofibrate-exposed pigs (P < 0.018).
There was no change in the activities with postnatal age
(P = 0.2). The total and inhibited enzyme activity (μmol/
h/g protein) were 31.2, 52.4 on average for the pigs at
delivery and 39.3, 64 on average for the 24 h-old pigs.
Hepatic ACO activity was increased by 2.3 fold in the
clofibrate-exposed pigs (P < 0.036; Figure 6B). The en-
zyme activity also increased by 1.4 fold in 24-h-old pigs,
but the increase had no influence on the degree of clofi-
brate stimulation (P > 0.05).
The relative mRNA expression of CPT I was increased by
19-fold in liver of the clofibrate-exposed pigs (P < 0.0001),
Figure 6 The effect of maternal clofibrate on enzyme specific activity in newborn pigs at birth and 24 h after delivery by C-section.
Hepatic activity of carnitine palmitoyltransferase (CPT, A) and acyl-CoA oxidase (ACO, B). Values are least square means ± SEM (n = 6 for pigs at
0 h and n = 4 for pigs at 24 h). *Significantly different from clofibrate and # significantly different from postnatal age (P < 0.05).
Figure 5 Percentage of peroxisomal fatty acid oxidation in total fatty acid oxidation. Values are least square means ± SEM (n = 6 for
newborn pigs at 0 h and n = 4 for pigs at 24 h). *Significantly different from fatty acid (P < 0.05).
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abundance of either ACO or PPARα (P > 0.05, Figure 7).Discussion
Previous research in rodents has shown peroxisome pro-
liferation was observed in the liver of fetuses over 13
days and/or newborns from clofibrate treated dams
during gestation [15,23]. The peroxisomal membrane
protein 70 and the marker enzymes dihydroxyacetone
phosphate acyltransferase and catalase specific activ-
ities were significantly increased in the fetal liver of
mice at 19 d gestation [15]; indirectly suggesting that
clofibrate and/or its metabolites could cross the placenta
barrier to enter the circulation system of the fetus in ro-
dent species. However, there was no direct evidence to
demonstrate if clofibrate, clofibrate metabolites, or both
actually cross the placental barrier. Additionally, the
morphology and function of placenta vary greatly among
mammals [24]. The type of placenta in swine has been de-
scribed as a diffuse, folded, and epitheliochorial placenta
type that is different from that of rats, which has a dis-
coidal, labyrinthine, and hemotrichorial placenta type [25].
Considering the disparity between the morphology and
mechanisms for an extra embryonic membrane attach-
ment in swine, the placental transfer of clofibrate could be
different from the rodent species. The aim of this study is
to determine if clofibrate or its metabolites traverse por-
cine placental tissues to evaluate the effect of clofibrate on
lipid metabolism in the offspring of pregnant swine fed
clofibrate. Our result clearly established that clofibrate is
absorbed and hydrolyzed into clofibric acid, and the clo-
fibric acid crosses the porcine placenta with no chemical
or structural modifications. The results are also in line
with the previous observation that the biofunctional
activity of clofibrate is due to clofibric acid [26]. In
addition of the analytical results from plasma analyses,Figure 7 The effect of maternal clofibrate on mRNA expression
in newborn pigs at 0 h. mRNA expression was performed by
qtPCR in duplicates. Values (fold of control) are least square
means ± SEM (n = 6). *Significantly different from clofibrate (P < 0.05).the in vitro metabolism measurements strongly sup-
port that clofibric acid delivered via the maternal diet
entered fetal circulation and induced fetal hepatic fatty
acid oxidation. Feeding clofibrate to neonatal pigs for
14 days and to young pigs for 28 days caused a mild
increase in the liver weight as a percentage of body
weight (3.3%, [11]; 3.8%, [27]). The relative weight of
the liver (g/kg body weight) measured in this study
showed no difference between the pigs from the clofi-
brate treated group (26.9 ± 0.09) and control group
(27.9 ± 0.15), suggesting that exposure to the pharma-
cological PPARα agonist clofibrate by sows for 9 days
during late pregnancy would not cause a morpho-
logical change in the liver of the offspring. Although
we did not perform a histological examination, clofi-
brate has no substantial effect on the peroxisome prolifer-
ation in this species at the ages of 7 days and 8 weeks [28].
This is similar to humans but significantly different from
the rodent species in which activation of PPARα by clofi-
brate initiates hepatocyte proliferation and induces the
well-known hepatocellular carcinoma [29,30].
Evidence from rodent species demonstrated that maternal
supplementation of clofibrate orally or by injection stimu-
lates peroxisomal proliferation, decreases oxygen uptake,
and alters lipid metabolism in the liver and intestine of
fetuses or neonates. Maternal clofibrate induces cyto-
chrome P4504A mRNA expression [16] and increases
ACO and catalase specific activities in the fetal liver
and kidneys [31]. Recently, the high relative mRNA expres-
sion of PPARα target genes ACO, CPT I, medium- and
long-chain acyl-CoA dehydrogenases were observed also
in the liver of fetuses from pregnant rats fed with clofibrate
and oxidized fat [17]. However, as PPARα is a crucial regu-
lator of lipid metabolism, the role of its activation of target
genes in fatty acid oxidative metabolism in the fetal and/or
neonatal liver from the pregnant animals receiving clofi-
brate has not been determined in previous studies. In the
current study, we examined both peroxisomal and mito-
chondrial β-oxidation using 14C-labeled long-chain fatty
acids C18:1 and C24:0. Results from this study indeed
demonstrated that maternal feeding of clofibrate increases
hepatic fatty acid oxidation in the pig’s liver at birth and
24 h after birth. The increase appears to be associated with
the enhanced CPT I and ACO specific activities in the
liver. The results achieved in the newborns exposed to
clofibrate prenatally via the maternal diet were similar
to the increase in vitro and vivo fatty acid oxidation re-
ported in neonatal pigs receiving clofibrate directly postna-
tally [10,13]. Because the increase of CPT I specific activity
was congruent with the great increase in mRNA expres-
sion, the stimulation of fatty acid oxidation in the liver, par-
ticularly in the mitochondria, resulted from the gene
expression potentially due to the activation of PPARα by
clofibrate. In contrast with CPT I, however, the expressions
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in clofibrate-exposed pigs. This suggests that other factors
might be involved in the upregulation of ACO specific
activity. Data from studies with rodent fetuses indi-
cated that PPARα mRNA expression is associated with
the postpartum age and hormonal and/or nutritional
status of the mother. The induction of liver PPARα
mRNA expression occurs around birth and the expres-
sion maintains an elevated level throughout the suck-
ling period [32], while the content of peroxisomes and
the activity of peroxisomal enzymes appear to occur in
late fetal development and peak dramatically at birth
[33]. These results imply that the ACO protein and
PPARα mRNA might have reached pinnacle expression
at birth. Indeed, the increase in relative PPARα mRNA
was not observed in the liver from clofibrate fed rats
in a study conducted by Ringseis et al. [34]. They sug-
gested that endogenous free fatty acids might reduce
the capability of fibrates to active PPARα, and conse-
quently its metabolic effects, because ACO is the enzyme
containing PPAR response element and responds to
changes in polyunsaturated fatty acid levels in a PPARα–
dependent manner. Furthermore, a different physiological
status, such as a fasting state, might provoke a different
PPARα response in the liver of fetuses. The induction of
peroxisomal oxidation occurs immediately postpartum, is
greater in the suckled versus fasted neonatal pigs, and is
reliant on the initiation of suckling [35]. Thus, the lower
response in mRNA expressions of ACO and PPARα might
be due to the developmental stage and the physiological
status of the fetuses because the mRNA of PPAR α was
also measured in a fasted state in this study.
The effect of the developmental ages of fetuses on oral
food intake and gastrointestinal digestion has been described
in humans and animals [36,37], but information on the en-
ergy metabolism in the fetus is very limited after delivery.
Results from earlier studies showed that hepatocytes isolated
from term guinea pigs were unable to oxidize fatty
acids, but the capability was developed in the first 12 h
after birth. The production of 14C measured in CO2
and ASP from 1-14C labeled fatty acids at 6 h was 40–50%
of the production at 24 h. At 12 h of age the rate of fatty
acid oxidation had already reached the rate at 24 h and
did not change during suckling in the first week of life.
These data show that the capacity for β-oxidation and
ketogenesis develops maximally in this species during
the first 6–12 h after birth, and appears to be partly
dependent on the development of fatty acid-activating
enzymes [38]. Similarly, a low fatty oxidation rate with
a high esterification was also observed in hepatocytes
isolated from term fetal rabbits, whatever the octano-
ate concentration in the medium [39]. Consistent with
the observations in term guinea pigs and rabbits, the
fatty acid oxidation obtained in term pigs at the timeof delivery by C-section was also low even when com-
pared with the rate measured in newborn pigs born
naturally [5]. The low fatty acid rate was increased signifi-
cantly in the first 24 h, in which the rate was increased
2.3 fold in mitochondria and 1.9 fold in peroxisomes.
However, the increase in mitochondria apparently was
not due to an increase of the key enzyme CPT I activity.
The activity measured at 24 h was not significantly differ-
ent from the activity measured at 0 h after the delivery.
A similar phenomenon was also observed in newborn
and 24 h fasted pigs [5]. The increase might be associ-
ated with an increase in the number of mitochondria
observed in neonatal pigs during in the first 12 h [40]
and/or a decrease of sensitivity of CPT I to malonyl-CoA
inhibition observed in 24-h-old pigs [5]. In contrast with
mitochondria, the increase of fatty acid oxidation in
peroxisomes was accompanied with a 2.3 fold increase
of the ACO. Even so, it is notable that the oxidation
rate of C24:0 was not significantly promoted during
the first 24 h in peroxisomes, suggesting differences
between mitochondria and peroxisomes in the capabil-
ity of oxidizing fatty acids. Because the very long-chain
fatty acid exclusively is activated in micorosomes or/
and peroxisomes, the low fatty acid oxidation might be
associated with a low activity of very long-chain acyl-
CoA synthetase. These results imply the impact of
postpartum age on the metabolic pathway varied among
subcellular compartments.
Peroxisomal fatty acid oxidation catalyzes chain-length
shortening of monounsaturated fatty acid and saturated
very long-chain fatty acid. Evidence indicated that C24:0
could only be oxidized initially in peroxisomes after acti-
vation by the acyl-CoA sythetase enzyme in endoplasmic
reticulum and peroxisomes in brain and liver [41,42].
Peroxisomes at least have two enzyme systems for fatty
acid activation: 1 for long-chain fatty acid and 2 for
very-long-chain fatty acid [42]. Indeed, there was no
substantial 14C accumulation in either CO2 or ASP or
both of CO2 and ASP from C24:0 in mitochondria.
Neither clofibrate-exposure nor age had any influence
on the definitely negligible mitochondrial 14C accumu-
lation from C24:0 (≤1%). The percentage of C24:0 oxida-
tion in peroxisomes was more than 80% of the total
oxidation. Clofibrate had no effect on the relative oxida-
tive capacity of peroxisomes although the efficacy of
clofibrate was increased by postpartum age. This result
suggests that the very long-chain fatty acid is catabolized
exclusively in peroxisomes. In contrast with C24:0,
high14C accumulations in CO2, ASP and CO2 + ASP
from C18:1 were observed in both mitochondria and
peroxisomes, suggesting that C18:1can be oxidized
initially in both of the organelles. Similar results were
observed also using C18:1 and erucic acid as sub-
strates in our previously study [13].
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In conclusion, clofibrate from maternal oral feeding dur-
ing gestation is absorbed and hydrolyzed to clofibric
acid, which can cross the porcine placenta and enter the
fetal circulation system. Fetuses that were exposed to clo-
fibric acid via maternal-placental transfer had a higher
hepatic capacity to oxidize fatty acid at birth as compared
to control fetuses. The high fatty acid oxidative capacity
resulted from an increase in key enzyme activities induced
by clofibric acid via activation of PPARα and its target
genes. The promoted fatty acid oxidation by activation of
PPARα and its target genes was attenuated in fasted
newborns with postpartum age. Postpartum age also
increased fatty acid oxidation. The increase was associated
with development and was not influenced by clofibrate
supplementation. Results from this study suggest that clofi-
brate could be examined as an agent to induce precocious
development of ACO and possibly improve milk fat oxida-
tion and pig survivability.
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